Show Summary Details
Page of

Papillary, follicular, and anaplastic thyroid carcinoma and lymphoma 

Papillary, follicular, and anaplastic thyroid carcinoma and lymphoma
Papillary, follicular, and anaplastic thyroid carcinoma and lymphoma

Sophie Leboulleux

and Martin Jean Schlumberger

Page of

PRINTED FROM OXFORD MEDICINE ONLINE ( © Oxford University Press, 2022. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 18 May 2022

Papillary and follicular thyroid carcinomas are the most frequent forms of thyroid cancers and are among the most curable cancers. However, some patients are at high risk of recurrence or even death from their cancer, and can be identified at the time of diagnosis using well-established prognostic indicators (1–3). The apparent increase in the incidence of thyroid carcinomas observed in recent years is mainly related to an increased detection of low risk small carcinomas in adults, which is attributed to an improvement in diagnostic techniques (4, 5). This leads to the treatment of an increasing number of low-risk patients for whom an optimal quality of life should be maintained. However, the number of high-risk patients remains unchanged and these patients require aggressive treatment and follow-up. The extent of initial treatment and follow-up should therefore be individualized according to recent guidelines and consensus (6, 7).

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.